Is there a correlation between the aggressiveness of chronic asymptomatic prostatitis NIH category IV and the Gleason score in patients with prostate cancer?

Abstract

Introduction: We evaluated the correlation between the International Society of Urological Pathology (ISUP) grades and the aggressiveness grades of prostate inflammation in newly diagnosed prostate cancer patients with chronic asymptomatic prostatitis National Institiutes of Health (NIH) category IV (CAPNIHIV).
 Methods: The study comprised 357 consecutive patients with prostate cancer in whom a cancer diagnosis had been made via a prostate needle biopsy. Histological sections of the prostate biopsy specimens of the patients were reviewed and scored. Prostatic inflammation was scored using the aggressiveness grade of inflammation. The associations between the ISUP grades and the aggressiveness grades of inflammation were analyzed using logistic regression. The limitations of the study were its retrospective design and the limited number of cases.
 Results: In 110 (31%) patients, CAPNIHIV was detected: 56 (51%) patients had a grade 0 aggressiveness score, 34 (31%) patients had a grade 1 aggressiveness score, and 20 (18%) patients had a grade 2 aggressiveness score. The patients who had prostatic inflammation had a 1.65 times (95% confidence interval [CI] 1.05–2.61) greater likelihood of a high ISUP grade (grade ≥3) compared with the patients who did not have prostatic inflammation. The association between the ISUP grade and the aggressiveness grade of inflammation was more pronounced for a grade 2 aggressiveness score (n= 20; odds ratio 2.97; 95% CI 1.14–7.71).
 Conclusions: In prostate cancer patients with CAPNIHIV, there was a positive correlation between the inflammation aggressiveness grade and the ISUP grade. The aggressiveness of intraprostatic inflammation may be an important morphological factor affecting the Gleason score.

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

“…In summary, whether metformin use can reduce the risk of bacterial prostatitis has not been researched but it is possible that metformin may reduce the risk of prostatitis through indirect effects of improving glycemic control and its anti-microbial and anti-inflammatory properties. Because chronic inflammation associated with prostatitis may predispose to the development of PCa [ 78 80 81 82 ], metformin's effect on prostatitis is an issue worthy of more in-depth investigation.…”

“…Chronic inflammation resulting from prostatitis, BPH, or other etiologies may promote the development of PCa and is a promoter of metastasis and therapeutic resistance in PCa [ 78 80 81 ]. The use of metformin as an anti-inflammatory agent in the management of PCa has also been proposed [ 103 104 ].…”

Inflammation induced by lipopolysaccharide advanced androgen receptor expression and epithelial-mesenchymal transition progress in prostatitis and prostate cancer

“…Chronic asymptomatic prostatitis was detected in 31% patients with PCa, and there was a positive correlation between the inflammation aggressiveness grade and urological pathology grades. The aggressiveness of intraprostatic inflammation may be an important morphological factor affecting the Gleason score (13). In prostate lesions, focal prostate inflammatory atrophy (PIA) or high-grade prostate intraepithelial neoplasia (HGPIN) is often associated with infiltrating immune cells (14), which have been discussed in connection with early cancer development (15).…”

Plasma IL‐6 and TNF‐α levels correlate significantly with grading changes in localized prostate cancer

“…In particular, chronic inflammation provided a suitable immune microenvironment for tumor proliferation and progression 7 . Some clinical studies believed a positive relationship between chronic inflammation in the prostate and Gleason score (GS) upgraded or tumor progression 8,9 . Pro‐inflammatory cytokines might play important roles in promoting the survival and proliferation of tumor cells.…”